Jason Karlawish, MD and Emily Largent, PhD from the IMPACT Collaboratory Ethics and Regulation Core wrote an editorial reflecting on the unique ethical complexities around telling participants in an Alzheimer’s drug study that the study had abruptly ended. The story was also covered in the New York Times.
Building the nation’s capacity to conduct pragmatic clinical trials embedded within healthcare systems for people living with dementia and their care partners